Cargando…
Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder
Bladder pathologies, very common in the aged population, have a considerable negative impact on quality of life. Novel targets are needed to design drugs and combinations to treat diseases such as overactive bladder and bladder cancers. A promising new target is the ubiquitous Rho GTPase Rac1, frequ...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219850/ https://www.ncbi.nlm.nih.gov/pubmed/35740379 http://dx.doi.org/10.3390/biomedicines10061357 |
_version_ | 1784732222873403392 |
---|---|
author | Sauzeau, Vincent Beignet, Julien Bailly, Christian |
author_facet | Sauzeau, Vincent Beignet, Julien Bailly, Christian |
author_sort | Sauzeau, Vincent |
collection | PubMed |
description | Bladder pathologies, very common in the aged population, have a considerable negative impact on quality of life. Novel targets are needed to design drugs and combinations to treat diseases such as overactive bladder and bladder cancers. A promising new target is the ubiquitous Rho GTPase Rac1, frequently dysregulated and overexpressed in bladder pathologies. We have analyzed the roles of Rac1 in different bladder pathologies, including bacterial infections, diabetes-induced bladder dysfunctions and bladder cancers. The contribution of the Rac1 protein to tumorigenesis, tumor progression, epithelial-mesenchymal transition of bladder cancer cells and their metastasis has been analyzed. Small molecules selectively targeting Rac1 have been discovered or designed, and two of them—NSC23766 and EHT 1864—have revealed activities against bladder cancer. Their mode of interaction with Rac1, at the GTP binding site or the guanine nucleotide exchange factors (GEF) interaction site, is discussed. Our analysis underlines the possibility of targeting Rac1 with small molecules with the objective to combat bladder dysfunctions and to reduce lower urinary tract symptoms. Finally, the interest of a Rac1 inhibitor to treat advanced chemoresistance prostate cancer, while reducing the risk of associated bladder dysfunction, is discussed. There is hope for a better management of bladder pathologies via Rac1-targeted approaches. |
format | Online Article Text |
id | pubmed-9219850 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92198502022-06-24 Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder Sauzeau, Vincent Beignet, Julien Bailly, Christian Biomedicines Review Bladder pathologies, very common in the aged population, have a considerable negative impact on quality of life. Novel targets are needed to design drugs and combinations to treat diseases such as overactive bladder and bladder cancers. A promising new target is the ubiquitous Rho GTPase Rac1, frequently dysregulated and overexpressed in bladder pathologies. We have analyzed the roles of Rac1 in different bladder pathologies, including bacterial infections, diabetes-induced bladder dysfunctions and bladder cancers. The contribution of the Rac1 protein to tumorigenesis, tumor progression, epithelial-mesenchymal transition of bladder cancer cells and their metastasis has been analyzed. Small molecules selectively targeting Rac1 have been discovered or designed, and two of them—NSC23766 and EHT 1864—have revealed activities against bladder cancer. Their mode of interaction with Rac1, at the GTP binding site or the guanine nucleotide exchange factors (GEF) interaction site, is discussed. Our analysis underlines the possibility of targeting Rac1 with small molecules with the objective to combat bladder dysfunctions and to reduce lower urinary tract symptoms. Finally, the interest of a Rac1 inhibitor to treat advanced chemoresistance prostate cancer, while reducing the risk of associated bladder dysfunction, is discussed. There is hope for a better management of bladder pathologies via Rac1-targeted approaches. MDPI 2022-06-08 /pmc/articles/PMC9219850/ /pubmed/35740379 http://dx.doi.org/10.3390/biomedicines10061357 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sauzeau, Vincent Beignet, Julien Bailly, Christian Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder |
title | Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder |
title_full | Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder |
title_fullStr | Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder |
title_full_unstemmed | Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder |
title_short | Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder |
title_sort | rac1 as a target to treat dysfunctions and cancer of the bladder |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219850/ https://www.ncbi.nlm.nih.gov/pubmed/35740379 http://dx.doi.org/10.3390/biomedicines10061357 |
work_keys_str_mv | AT sauzeauvincent rac1asatargettotreatdysfunctionsandcancerofthebladder AT beignetjulien rac1asatargettotreatdysfunctionsandcancerofthebladder AT baillychristian rac1asatargettotreatdysfunctionsandcancerofthebladder |